Services

Medical Devices In Vitro Diagnostics

Clinical Evaluation Consultant

Clinical evaluation consultant for EU MDR compliance

Clinical evaluation under EU MDR has become one of the most challenging regulatory requirements for medical device manufacturers. Companies are expected to establish a robust Clinical Evaluation Plan (CEP), continuously maintain compliant medical device technical file documentation, and prepare a scientifically justified Clinical Evaluation Report(CER) that demonstrates device safety, clinical performance, and benefit-risk acceptability in accordance with Article 61 and Annex XIV requirements. In practice, many manufacturers struggle with insufficient clinical evidence, inconsistent literature reviews, gaps in state-of-the-art analysis, and increasing scrutiny from notified bodies during MDR conformity assessment procedures. Under Annex XIV, the Clinical Evaluation Report and supporting clinical evidence are considered essential parts of the technical documentation and must be continuously maintained throughout the product lifecycle.

At Billev Pharma East, we provide strategic and scientific support as a trusted

Clinical Evaluation Consultant

for EU MDR compliance. Our team helps manufacturers develop compliant Clinical Evaluation Plans, prepare and update Clinical Evaluation Reports, and strengthen their overall clinical evidence strategy throughout the product lifecycle. We combine regulatory affairs, medical consultancy, and scientific expertise to support

companies preparing for CE marking, updating legacy device documentation, addressing notified body findings, and maintaining ongoing MDR compliance requirements.

How to Reach us?

Billev farmacija vzhod, d. o. o.
Billev Pharma East Ltd.
Tržaška cesta 202

1000 Ljubljana

Slovenia

How Billev Pharma East supports you as a clinical evaluation consultant

As an experienced Clinical Evaluation Consultant, we help medical device manufacturers develop and maintain compliant clinical documentation aligned with EU MDR requirements, notified body expectations, and broader medical device regulatory consulting strategies. Our support covers the complete clinical evaluation process, from early regulatory strategy and Clinical Evaluation Plan development to Clinical Evaluation Report preparation, clinical data appraisal, literature review, and integration within the overall medical device technical file. EU MDR Annex XIV requires manufacturers to continuously generate, collect, analyse, and assess clinical evidence demonstrating device safety, performance, and benefit-risk acceptability throughout the product lifecycle.

We support companies in preparing scientifically robust Clinical Evaluation Reports (CERs) that align with Article 61 and Annex XIV requirements while addressing common regulatory gaps identified during notified body reviews. Our team also develops structured Clinical Evaluation Plans (CEPs) that define the clinical evaluation methodology, literature search strategy, clinical endpoints, and benefit-risk framework necessary for MDR compliance for medical devices. In addition, we help manufacturers strengthen state-of-the-art analysis, equivalence justification, PMCF integration, and ongoing clinical evidence maintenance to support both initial CE marking and long-term market access. Clinical evaluation documentation forms an essential part of the medical device technical documentation reviewed during conformity assessment procedures.

What companies must do for clinical evaluation under EU MDR

Under EU MDR, manufacturers are required to plan, conduct, document, and continuously update the clinical evaluation process throughout the entire device lifecycle. Companies must establish a compliant Clinical Evaluation Plan (CEP), identify and appraise relevant clinical evidence, and prepare a scientifically justified Clinical Evaluation Report (CER) demonstrating device safety, performance, and benefit-risk acceptability in accordance with Article 61 and Annex XIV requirements. Clinical evaluation is no longer considered a one-time regulatory exercise, but an ongoing process integrated into post-market surveillance and PMCF activities.

Manufacturers are also expected to justify the level of clinical evidence required for their device, establish state-of-the-art analysis, evaluate available clinical literature, address equivalence requirements where applicable, and maintain alignment between clinical data, risk management, and technical documentation. In many cases, notified bodies identify gaps related to insufficient literature appraisal, weak benefit-risk justification, incomplete Clinical Evaluation Reports, or inconsistencies between the Clinical Evaluation Plan and the final CER. EU MDR Article 61 specifically requires manufacturers to follow a defined and methodologically sound clinical evaluation procedure supported by continuously updated clinical evidence.

Why companies work with a clinical evaluation consultant

EU MDR clinical evaluation requirements have become increasingly complex, particularly for manufacturers preparing technical documentation for CE marking or responding to notified body findings. Many companies lack the internal regulatory, medical, and scientific resources needed to develop a compliant Clinical Evaluation Plan, maintain a robust Clinical Evaluation Report, and continuously manage clinical evidence throughout the device lifecycle. As regulatory expectations continue to evolve, manufacturers are under growing pressure to demonstrate sufficient clinical evidence, justify equivalence claims, maintain alignment with PMCF activities, and ensure consistency across all MDR documentation.

Working with an experienced Clinical Evaluation Consultant helps companies strengthen their clinical evaluation strategy while reducing regulatory gaps that commonly delay conformity assessment procedures. Independent clinical evaluation support can help manufacturers improve the quality of Clinical Evaluation Reports, establish structured Clinical Evaluation Plans, align clinical evidence with General Safety and Performance Requirements (GSPRs), and prepare documentation that withstands notified body scrutiny. Under Article 61 and Annex XIV, manufacturers are expected to follow a defined and methodologically sound clinical evaluation process supported by continuously updated clinical evidence and PMCF activities.

Build a stronger clinical evaluation strategy under EU MDR

A compliant Clinical Evaluation Report and a well-structured Clinical Evaluation Plan are essential components of successful EU MDR compliance and long-term market access. As regulatory expectations continue to evolve, manufacturers must maintain robust clinical evidence, continuously update clinical evaluation activities, and ensure alignment between CER documentation, PMCF activities, risk management, and technical documentation. Under Article 61 and Annex XIV, clinical evaluation is considered an ongoing lifecycle process requiring systematic collection and assessment of clinical data to demonstrate device safety, performance, and benefit-risk acceptability.

At Billev Pharma East, we support manufacturers with practical and scientifically driven Clinical Evaluation Consultant services tailored to EU MDR requirements, notified body expectations, and long-term regulatory compliance objectives. Whether companies require support with Clinical Evaluation Report preparation, Clinical Evaluation Plan development, CER remediation, or ongoing clinical evidence strategy, our team helps strengthen clinical documentation and support a more efficient path toward MDR compliance.

More ways,
we can help.

With a focus on expert guidance and strategic insights, we propel your projects forward with confidence, ensuring every step is handled with precision.

Don’t miss out

Follow us on LinkedIn

Watch our
promotional video

HOME

SERVICES

Regulatory Affairs

PharmacoVigilance

Medical Consultancy

Quality / GxP

Digital Consultancy

TEAM OF EXPERTS

ABOUT US

NEWS AND EVENTS

B2B PARTNER LOG-IN